Targeted Therapy and Immunotherapy for Lung Cancer

Targeted therapy and immunotherapy have changed the treatment paradigm of non-small cell lung cancer (NSCLC). Distinct molecular subtypes of NSCLC have been described over the past 20 years, enabling the emergence of treatments specific to that subtype. Agents targeting the driver mutations in NSCLC...

Full description

Saved in:
Bibliographic Details
Published inSurgical oncology clinics of North America Vol. 25; no. 3; p. 601
Main Authors Naylor, Evan C, Desani, Jatin K, Chung, Paul K
Format Journal Article
LanguageEnglish
Published United States 01.07.2016
Subjects
Antineoplastic Agents - therapeutic use
Carcinoma, Non-Small-Cell Lung - immunology
Carcinoma, Non-Small-Cell Lung - metabolism
Carcinoma, Non-Small-Cell Lung - therapy
Humans
Immunotherapy
Lung Neoplasms - immunology
Lung Neoplasms - metabolism
Lung Neoplasms - therapy
Molecular Targeted Therapy
Mutation
Treatment Outcome
Non–small cell lung cancer
Molecular
Targeted therapy
Immunotherapy
Online AccessGet more information

Cover

More Information
Summary:Targeted therapy and immunotherapy have changed the treatment paradigm of non-small cell lung cancer (NSCLC). Distinct molecular subtypes of NSCLC have been described over the past 20 years, enabling the emergence of treatments specific to that subtype. Agents targeting the driver mutations in NSCLC have revolutionized the approach to patients with metastatic disease, because oncologists now select a treatment based on the profile of that particular tumor. More recently, an understanding of immune checkpoints has led to the development of checkpoint inhibitors that enable the host immune system to better recognize tumor cells as foreign and to destroy them.
ISSN:1558-5042
DOI:10.1016/j.soc.2016.02.011